Clinical Trials Browser

Phase 3 × Primary Myelofibrosis × 1 year × Clear all

NCT04562389 2026-04-09

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06351631 2026-04-02

MK-3543-017

Phase 3 Recruiting

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04472598 2026-03-23

TRANSFORM-1

Phase 3 Completed

252 enrolled 17 charts

Neoplasms, Primary Myelofibrosis

NCT05198960 2026-03-20

AVAJAK

Phase 3 Recruiting

Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

Phase 3 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Phase 3 Active not recruiting

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3 Terminated

252 enrolled 18 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03952039 2025-08-28

FREEDOM2

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04717414 2025-07-10

INDEPENDENCE

Phase 3 Active not recruiting

Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis